There are 2934 resources available
3464 - BACCI: A Phase II Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Capecitabine (C) Bevacizumab (B) plus Atezolizumab (A) or Placebo (P) in Refractory Metastatic Colorectal Cancer (mCRC): An ACCRU Network Study
Presenter: Niharika Mettu
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
5073 - Association between transit-amplifying signature and outcomes of patients treated with anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer
Presenter: Elisa Fontana
Session: Poster Discussion – Gastrointestinal tumours, colorectal
Resources:
Abstract
4447 - Prognostic factors in metastatic seminomatous germ cell tumors and elevated human chorionic gonadotrophin (HCG) – a study of the G3
Presenter: Christoph Seidel
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4145 - Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 countries
Presenter: Rachel Giles
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
2053 - Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)
Presenter: Michiel Van der Heijden
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4707 - NIVOREN GETUG-AFU 26 translational study:CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
Presenter: Yann Vano
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4823 - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
Presenter: Toni Choueiri
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3170 - A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC
Presenter: Eric Jonasch
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4174 - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4138 - ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.
Presenter: Lewis Au
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract